International Journal of Endocrinology / 2013 / Article / Tab 4

Clinical Study

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)

Table 4

Changes in inflammatory markers.

ParametersGroup0 month12 monthsP-valueDifferenceP-value

Hyaluronic acid (ng/mL)T 0.091
L 0.345 0.310
7S domain of type 4 collagen (ng/mL)T 0.723
L 0.834 0.419
High-sensitivity C-reactive protein (mg/dL)T 0.155
L 0.176 0.077
Procollagen-3-peptide (U/mL)T 0.656
L 0.351 0.766
Zinc (μg/dL)T 0.139
L 0.735 0.374
Total adiponectin (μg/mL)T 0.553
L 0.753 0.561
Interleukin-6 (pg/mL)T 0.158
L 0.173 0.766

Data are presented as mean SD. Parameters at 0 and 12 months of treatment were compared by Wilcoxon's matched-pair signed-rank test. Differences are shown as [value at 12 months − value at 0 month]. Differences between groups (telmisartan (T) versus losartan (L)) were compared by Mann-Whitney test.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.